key: cord-0773288-0kceuc2i
authors: Blickstein, Dorit; Koren Michowitz, Maya
title: Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine: Reply to comment from Doyle et al.
date: 2022-02-26
journal: J Thromb Haemost
DOI: 10.1111/jth.15634
sha: 67759a4cdacfc0c4df0ff20905b88dec183a919d
doc_id: 773288
cord_uid: 0kceuc2i

nan

There are reports on aTTP association with other vaccines (e.g., H1N1 vaccine, pneumococcal vaccine) as mentioned in our report, 1 so that COVID-19 vaccine-aTTP association is not different from previously described vaccine-associated aTTP.

Interestingly, the third BNT162b2 vaccine in Israel was associated with immune thrombocytopenic purpura (ITP) and not aTTP (data not reported yet), suggesting that there may be a dosedependent immune modulation.

aTTP associated with BNT162b2 vaccine is rare; therefore, we strongly support the use of COVID-19 vaccines in the general population including aTTP patients. As discussed in our report, we suggest having protective measures before and after COVID-19 vaccination in aTTP patients. 1 We strongly agree with the authors for the need of reporting aTTP presentations following COVID-19 vaccination to a national reporting system scheme.

The authors declare no competing financial interests. 

Acquired thrombotic thrombocytopenic purpura: a rare disease associated with BNT162b2 vaccine

First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination

Immune-mediated thrombotic thrombocytopenic purpura following Pfizer-BioNTech COVID-19 vaccine

Recurrence of thrombotic thrombocytopenic purpura after mRNA-1273 COVID-19 vaccine administered shortly after COVID-19

Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-Oxford COVID-19 vaccine

Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine

Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination